Loading...
Please wait, while we are loading the content...
Similar Documents
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
| Content Provider | Semantic Scholar |
|---|---|
| Author | Drucker, Daniel J. Nauck, Michael A. |
| Copyright Year | 2006 |
| Abstract | Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake. Therapeutic approaches for enhancing incretin action include degradation-resistant GLP-1 receptor agonists (incretin mimetics), and inhibitors of dipeptidyl peptidase-4 (DPP-4) activity (incretin enhancers). Clinical trials with the incretin mimetic exenatide (two injections per day or long-acting release form once weekly) and liraglutide (one injection per day) show reductions in fasting and postprandial glucose concentrations, and haemoglobin A1c (HbA1c) (1-2%), associated with weight loss (2-5 kg). The most common adverse event associated with GLP-1 receptor agonists is mild nausea, which lessens over time. Orally administered DPP-4 inhibitors, such as sitagliptin and vildagliptin, reduce HbA1c by 0.5-1.0%, with few adverse events and no weight gain. These new classes of antidiabetic agents, and incretin mimetics and enhancers, also expand beta-cell mass in preclinical studies. However, long-term clinical studies are needed to determine the benefits of targeting the incretin axis for the treatment of type 2 diabetes. |
| Starting Page | 1696 |
| Ending Page | 1705 |
| Page Count | 10 |
| File Format | PDF HTM / HTML |
| DOI | 10.1016/S0140-6736(06)69705-5 |
| PubMed reference number | 17098089 |
| Journal | Medline |
| Volume Number | 368 |
| Alternate Webpage(s) | https://api.elsevier.com/content/article/pii/S0140673606697055 |
| Alternate Webpage(s) | https://www.sciencedirect.com/science/article/pii/S0140673606697055?dgcid=api_sd_search-api-endpoint |
| Alternate Webpage(s) | http://www.glucagon.com/pdfs/LancetNov2006DruckerNauck.pdf |
| Alternate Webpage(s) | https://doi.org/10.1016/S0140-6736%2806%2969705-5 |
| Journal | The Lancet |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
